MedTrace Logo

Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer

NCT04868045 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2023-02-21

No results posted yet for this study

Summary

The purpose of this study is to find out whether people who have had thyroid cancer develop resistance to treatment with thyroid hormones after having received high doses of thyroid drugs for many years.

Conditions

Interventions

DRUG

Thyrotropin Releasing Hormone (TRH)

TRH administration will be given as a 200-mcg single IV bolus on Day 1 and Day 5.

DRUG

levothyroxine

Patients maintenance dose of levothyroxine will be taken throughout the study. On Day 1 and Day 5, the levothyroxine will be taken after the TRH test is complete. On Days 2- 4, the levothyroxine will be taken in the morning.

OTHER

Hypothyroidism QOL questionnaire

Administer standardized Hypothyroidism QOL questionnaire.

Sponsors & Collaborators

Principal Investigators

  • Stephanie Fish, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-27
Primary Completion
2023-02-15
Completion
2023-02-15
FDA Drug
Yes

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04868045 on ClinicalTrials.gov